Bin Su, Ph.D.
 Title: Professor
 Dept: Chemistry
 Office: SR 327
 Phone: 216-687-9219
 Address: 2121 Euclid Ave. SR 327, Cleveland, OH 44115

Courses Taught


Faculty Only:
Update Profile

Research Keywords:
Drug development, Cancer, African trypanosomiasis, Synthetic medicinal chemistry,
Ph.D., Pharmacy, The Ohio State University, 2006
M.S., Pharmacy, The Ohio State University, 2005
M.S., Medicinal Chemistry, Peking University, 2002
B.S., Medicinal Chemistry, Beijing Medical University, 1996
Brief Bio:
Dr.Su graduated from the Ohio State University in Dr. Bob Brueggemeier's group. Then he moved to City of Hope National Medical Center at LA to be further trained in cancer biology and molecular pharmacology related to translational researches by working with Dr. Shiuan Chen. He is well trained in synthetic medicinal chemistry, cancer biology, molecular endocrinology which enriched his expertise in drug design and development. He joined CSU at August 2009 and started his independent academic career. His lab focuses on synthetic medicinal chemistry in anti-cancer and anti-trypanosomiasis drug development.
Honors and Awards:
1999 Excellent Teaching Award, Beijing Medical University
2004    Donald T. WitiaK Graduate Student Award, College of Pharmacy, The Ohio State University                    
2012 Faculty Merit Recognition Award of Research (CSU)
2013 Faculty Merit Recognition Award of Research (CSU)
2014 Faculty Merit Recognition Award of Research (CSU)
2014    Mentor of year, McNair scholar
2016 Faculty Merit Recognition Award of Research (CSU)
2017 Faculty Merit Recognition Award of Research (CSU)
Research Interests:
Dr.Su's lab focuses on anti-cancer and anti-trypanosomiasis drug development
1. Hsp27 inhibitor development. The expression of heat shock proteins (Hsp) is increased under lethal conditions, which is a typical response when cancer cells are stressed by chemotherapies. Hsp27, a small heat shock protein, shows a very tight correlation with anti-cancer drug resistance. Its over-expression enhances the survival of cancer cells exposed to chemotherapeutic agents. Targeting Hsp27 is a novel strategy for cancer treatment. Our lab has identified lead compounds that inhibit Hsp27 activity, and we current perform lead optimization to improve the pharmacological activity of the compounds.
2. Selective tubulin inhibitors for the treatment of African trypanosomiasis. By collaborating with Dr. Bibo Li at BEGS, we screened the small molecule compound library generated in our lab with T.brucei cells that is the parasite causing African sleeping disease. Interestingly, we identified several lead compounds that selectively inhibited the parasite growth, and did not affect the mammalian cell proliferation. These compounds selectively interfere with parasite tubulin, and do not block the mammalian tubulin function. There is a great potential to develop cheap, easy make drug candidates for the treatment of this Neglected Tropical Disease.  
3. Lead optimization of HMBA, a cell differentiation agent. Hexamethylene bisacetamide (HMBA) is an agent showing promising anti-cancer activities. It has been investigated at national cancer institute in phase II clinical trial for cancer treatment. However, the dose related toxicity limited the further drug development. It is critical to develop more potent analogs which will show lower toxicity. Dr. Monica Montano at CWRU pharmacology collaborates with us to optimize this compound. So far, about 40 new analogs have been developed. Very fortunately, we identified one derivative that is much more active than HMBA. We focus on the molecular targets identification of HMBA and its analogs currently.
Teaching Areas:
Pharmacology, Organic chemistry, Medicinal Chemistry
Professional Affiliations:
Member of American Chemical Society
Member of American Association of Pharmaceutical Scientists
University Service:
Director of the chemistry undergraduate program
Professional Service:
Dr. Su is a reviewer on a routine basis for several journals including Journal of medicinal chemistry, European Journal of medicinal chemistry, ChemMedChem, Medicinal chemistry communication, Current medicinal chemistry, Cancer epidemiology, Tumor biology.
Research Grants:
Ongoing Research Support

1.Selective tubulin inhibitors with improved cell update for kinetoplastid infections
(Bin Su, PI) 7/1/2016-6/31/2019
Funding Agency: NIAID
Type: 2R15AI103889-01

2.RO1(PI: Wang, Bingcheng (CWRU), co-I: Su, Bin (CSU)) NIH, 1R01NS09695601
Proposal Title: Targeting EphA2 in Glioblastoma
Project Period Begin Date: 04/01/2016
Project Period End Date: 03/31/2021

Completed grants:

3.Scott Hamilton CARES initiative (Sergei vatolin, PI) 01/01/2012-12/30/2012
Title: Development of a Lead Non-Nucleoside DNA Methyltransferase Inhibitor for Use in   Hematological Malignancies
Agency: Cleveland Clinic
Role: Co-PI

4.Faculty Research Development grant  (Bin Su, PI)       07/01/2011-06/30/2012
Cleveland State University
Discovery of Dual PDE-5 and Tubulin inhibitors as anti-cancer agents

5. R15AI103889-01 Drug development of orally active anti-trypanosomiasis agents
NIH/ NIAIDs 1/2013-6/2016